Nexomic

Nexomic at ESMO 2026. That’s a wrap. 5 posters presented. More good conversations than we could count. Thank you to everyone who stopped by to discuss our work. The oncologists, researchers and partners who share our belief that AI can change how cancer is understood and treated. We leave Madrid energised, and we’re not slowing down. Next stop: the ESMO AI & Digital Oncology Congress in Berlin this November, where we’re excited to bring 10 presentations of our science to the stage. See you in Berlin. #ESMOImmuno26 #ImmunoOncology #CancerResearch #CancerImmunology #AdvancedTherapies #ESMOMeetings #ESMOAI #ESMOGERMANY

We’re attending ESMO Congress 2026 in Madrid, and we’re proud to be presenting five posters. Our posters: #2737 – A self-supervised multi-omic AI foundation model recovers prognostic subgroups across seven independent solid tumour cohorts #7878 – A pretrained multi-omic AI foundation model identifies eight prognostically distinct breast cancer subgroups in METABRIC #7766 – Pathway-guided multi-omic AI reconstructs missing RNA and DNA methylation profiles across 34 cancer types #7824 – DNA-only multi-omic AI identifies tumour primary site across 31 lineages for cancer of unknown primary #7967 – Multi-omic AI stratifies survival in immunotherapy-treated metastatic pancreatic cancer Together, these studies show how one multi-omic foundation model can support prognosis, subtyping, and treatment decisions across many cancer types. Come find us in the poster area on Saturday and Sunday.

Nexomic wins the Newsweek Global Al Impact Awards 2026: Best Outcomes, Diagnostics (Al Healthcare). This recognition highlights our work and commitment to decoding cancer biology through multiomic Al to advance more personalised cancer treatment. Read our feature in Newsweek: https:// newsweek.com/insights/decodi…

Nexomic is pleased to announce Prof. Solange Peters as a member of its Advisory Board. Her internationally recognised expertise in thoracic oncology, biomarker discovery, cancer immunotherapy and translational clinical research will strengthen Nexomic’s work in precision oncology and support the translation of multiomic AI into more precise, biology-driven treatment strategies.

Nexomic is pleased to announce 3 accepted poster presentations at the WIN Consortium Symposium 2026, taking place in Providence, Rhode Island, 2–3 October. Our research explores how multi-omic AI can reveal tumour biology and predict patient outcomes across cancer types. We look forward to sharing our work and connecting with colleagues in Providence.

We are proud to announce 10 accepted abstracts for Nexomic: 9 posters and 1 oral presentation at the ESMO AI & Digital Oncology Congress 2026, taking place in **Berlin, 16–18 November. Accepted poster abstracts: #564: A tumor agnostic multi-omic foundation model for zero-shot generalisation, low-label transfer and clinically relevant prediction #569: Matched-cohort comparison of multi-omic representation learning methods under a leakage-free held-out-patient protocol #570: Zero-shot survival prediction in tumour histologies unseen during multi-omic foundation-model pretraining #571: A tumor-agnostic multi-omic foundation model enriches for immunotherapy responders within PD-L1-low tumours #573: Transcriptome-only DeepOmic preserves clinically relevant survival prediction without comprehensive multi-omic profiling #574: A generative omics engine recovers transcriptomic biology from a single molecular assay, enabling assay-sparing precision oncology #593: A generative omics engine operates across incomplete molecular profiles without requiring a fixed assay panel #607: Pan-cancer reconstruction performance can materially overestimate patient-relevant, within-disease performance #610: Biological graph priors enable zero-shot prediction of CRISPR perturbation effects by a pan-cancer generative omics model Oral presentation: Beyond Biomarkers: Decoding Tumour Biology with Multiomic AI Presented by Prof. Humaid Al Shamsi, Professor of Oncology; Co-Founder & Chairman, Nexomic. We look forward to sharing how Nexomic is advancing frontier AI to decode tumour biology and enable more precise cancer care.

We’re attending Biomarkers, CDx & Precision Medicine US 2026 in San Diego, with members of the Nexomic leadership team on site. If you’re attending, reach out to connect and meet with us during the conference. 📍 San Diego, California 📅 23–24 September 2026

We’re partnering with Cancer Research Horizons to advance and validate our DeepOmic Foundation Model using high-quality, clinically linked colorectal cancer multi-omics data. This collaboration will support Nexomic in learning the complex biology underlying treatment response, resistance and disease progression, helping advance a more precise, biology-driven approach to oncology.

What if the right patients are already in the trial, but hidden? In our latest DECODE case study, outcome-blind, zero-shot multiomic AI identified a patient subgroup with a 53% objective response rate, versus 18% outside the subgroup. No response labels. No fine-tuning. No relationship to PD-L1. 3× higher ORR. Beyond PD-L1. This is what better patient enrichment can look like. Explore the full case study: nexomic.com/resources/enrich…

Nexomic is pleased to announce Prof. Khaled Musallam, MD, PhD as a member of its Advisory Board. His internationally recognised expertise in rare blood disorders, global clinical trials, real-world evidence and novel therapy development will strengthen Nexomic’s work in evidence generation and help translate AI-driven discoveries into meaningful patient outcomes.

Nexomic is pleased to announce Prof. Toni Choueiri as a member of its Advisory Board. His internationally recognised expertise in genitourinary oncology, kidney cancer and practice-changing clinical trials will strengthen Nexomic’s work in precision oncology and help translate multi-omic AI insights into biomarker-driven therapeutic strategies.

Nexomic is pleased to announce Prof. Salah-Eddin Al-Batran as a member of its Advisory Board. His internationally recognised leadership in gastrointestinal oncology, molecular profiling and practice-changing clinical trials, particularly in gastric and gastroesophageal cancers, will strengthen Nexomic’s work in precision oncology and help translate multi-omic AI insights into biomarker-guided therapeutic strategies.

Nexomic is pleased to announce Prof. Giuseppe Curigliano as a member of its Advisory Board. His internationally recognised expertise in breast cancer, early drug development and biomarker-driven clinical trials across solid tumours will strengthen Nexomic’s work in precision oncology and help translate multi-omic AI insights into next-generation therapeutic strategies.

Nexomic is pleased to announce Prof. Paolo Tarantino as a member of its Advisory Board. His internationally recognised expertise in antibody–drug conjugates (ADCs), particularly in breast cancer, will further strengthen Nexomic’s work in precision oncology and help advance the clinical translation of next-generation ADCs across solid tumours.

Molecular Monday | week 5 Inherited or acquired? Driver or passenger? Not all cancer-related mutations are the same. Here’s the difference. ↓ #MolecularMonday #CancerResearch #Genomics

We are excited to announce a new partnership between Nexomic and Genomics England. This partnership will enable us to validate DeepOmic, our tumour-agnostic foundation model, using large-scale multi-omics data from cancer patients. Read more: nexomic.com/resources/nexomi…

Announcing a new partnership to de-risk oncology drug development and clinical trials. Nexomic is partnering with Alpha Clinical Development to bring DECODE, Nexomic’s AI-powered multi-omic intelligence solution, into oncology clinical development programmes. By combining Alpha Clinical Developments’ clinical trial strategy expertise with Nexomic’s ability to decode the biology of treatment response and resistance, we aim to help sponsors define biologically relevant patient populations and inform trial design, biomarker strategy, patient stratification and enrichment, enabling better development decisions earlier. Read more: nexomic.com/resources/nexomi…

Nexomic is pleased to announce Prof. Massimo Cristofanilli as a member of its Advisory Board. His internationally recognised expertise and leadership in precision oncology will strengthen Nexomic’s mission to translate advanced cancer biology into meaningful clinical impact